Palatin Technologies, Inc. (PTN)
Stock Price:
$0.590 USD
0.013 (2.32%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $0.590 -0.001 (-0.09%) Aug 3, 8:00 PM
Key Info
| Market Cap |
135.26M |
| Revenue (ttm) |
60.38M |
| Net Income (ttm) |
37.10M |
| Shares Out |
229.26M |
| EPS (ttm) |
0.15 |
| PE Ratio |
3.93 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$0.590 |
| Previous Close |
$0.577 |
| Change ($) |
0.013 |
| Change (%) |
2.32% |
| Day's Open |
0.593 |
| Day's Range |
0.578 - 0.600 |
| Day's Volume |
1,303,012 |
| 52-Week Range |
0.355 - 1.130 |
More Stats
| Market Cap |
135.26M |
| Enterprise Value |
46.31M |
| Earnings Date (est) |
Sep 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
229.26M |
| Float |
211.66M |
| EPS (basic) |
0.19 |
| EPS (diluted) |
0.15 |
| FCF / Share |
0.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
25.42% |
| FCF Yield |
29.86% |
| Payout Ratio |
n/a |
| Shares Short |
11.07M |
| Short Ratio |
2.85 |
| Short % of Float |
4.89% |
| Beta |
1.55 |
| PE Ratio |
3.93 |
| Forward PE |
n/a |
| P/FCF Ratio |
3.35 |
| PS Ratio |
2.24 |
| PB Ratio |
1.52 |
| Revenue |
60.38M |
| Operating Income |
35.97M |
| Net Income |
37.10M |
| Free Cash Flow |
40.39M |
| Net Cash |
88.95M |
| Net Cash / Share |
0.39 |
| Gross Margin |
75.26% |
| Operating Margin |
59.57% |
| Profit Margin |
61.40% |
| FCF Margin |
66.90% |
| ROA |
40.48% |
| ROE |
72.21% |
| ROIC |
272.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$2.17*
(267.80% upside)
Low
1.50
Current: $0.590
High
3.00
Target: 2.17
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 60.30 | 67.13 | 44.72 | - | 12.95 | - | 0.01 | 0.07 | 1.48 | 14.18 |
| Revenue Growth | -10.18% | 50.11% | - | - | - | - | -85.95% | -95% | -89.6% | - |
| Gross Profit | 60.30 | 67.13 | 44.72 | - | 12.95 | - | 0.01 | 0.07 | 1.48 | 14.18 |
| Operating Income | 35.74 | 25.93 | -10.57 | -49.25 | -17.29 | -15.79 | -15.59 | -18.79 | -13.65 | -3.01 |
| Net Income | 35.77 | 24.70 | -13.33 | -51.71 | -17.67 | -13.93 | -20.86 | -17.25 | -12.82 | -1.79 |
| Shares Outstanding | 208 | 198 | 184 | 157 | 121 | 107 | 97.62 | 34.90 | 20.08 | 9.86 |
| Earnings Per Share | 0.16 | 0.12 | -0.07 | -0.33 | -0.15 | -0.13 | -0.21 | -0.49 | -0.64 | -0.18 |
| EPS Growth | 33.33% | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow | -21.78 | 1.70 | 12.88 | -47.36 | -13.36 | -12.21 | -13.65 | -15.49 | -11.03 | -5.73 |
| Capital Expenditures | -0.04 | -0.02 | -0.13 | -0.02 | - | -0.01 | -0.05 | 0.48 | 0.01 | 0.04 |
| Free Cash Flow | -21.82 | 1.68 | 12.75 | -47.38 | -13.36 | -12.21 | -13.70 | -15.01 | -11.02 | -5.69 |
| Cash & Equivalents | 43.51 | 38.00 | 40.45 | 9.38 | 27.30 | 12.18 | 24.42 | 4.18 | 19.22 | 9.34 |
| Total Debt | 0.33 | 6.28 | 14.12 | 19.52 | 9.85 | - | 0.02 | 0.04 | 0.08 | 0.03 |
| Net Cash / Debt | 43.18 | 31.72 | 26.33 | -10.14 | 17.45 | 12.18 | 24.40 | 4.14 | 19.14 | 9.31 |
| Assets | 105 | 39.02 | 56.83 | 10.86 | 29.47 | 12.56 | 25.07 | 5.38 | 21.17 | 12.39 |
| Liabilities | 4.19 | 12.05 | 62.00 | 28.44 | 17.27 | 2.77 | 2.10 | 3.55 | 2.98 | 3.07 |
| Book Value | 101 | 26.96 | -5.16 | -17.59 | 12.20 | 9.79 | 22.98 | 1.83 | 18.19 | 9.32 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Palatin Technologies, Inc. |
| Country |
United States |
| Employees |
18 |
| CEO |
Carl Spana |
Stock Information
| Ticker Symbol |
PTN |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: PTN |
| IPO Date |
October 28, 1993 |
Description
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.